Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

GuideUpdated 6 min read

How to get retatrutide: clinical trials, expanded access, and the law

Retatrutide is not approved, so a clinical trial or FDA expanded access is the only lawful route. How to search ClinicalTrials.gov, how both work, and why online and compounded sources are unlawful.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: the main lawful way to get retatrutide today is to enroll in a registered clinical trial. A small pre-approval expanded access program also exists for adults with severe, treatment-resistant obesity, but a physician has to request it. Retatrutide is not FDA approved, no pharmacy can lawfully compound it, and the manufacturer describes it as a molecule that cannot be legally sold or marketed for human use. [1]

That leaves many people who search "how to get retatrutide" with a real problem: they want strong weight loss now. The approved drugs in the same family, tirzepatide and semaglutide, are available by prescription, and this guide ends with how to reach them. It does not cover dosing.

Where can you get retatrutide legally?

Retatrutide is investigational. In its own trial announcements, the manufacturer states that the drug is legally available only to participants in its clinical trials. [2] That rules out every other channel in the United States:

  • Pharmacies: there is no approved product to dispense.
  • Compounding pharmacies and outsourcing facilities: FDA states that retatrutide cannot be used in compounding under federal law, because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition. [6] It does not appear on the 503A bulk substance lists. [7]
  • Telehealth: FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers. [6]

The legal detail is logged on the retatrutide regulatory tracker, and our legal hub explains how federal and state rules apply to peptides generally.

How to find a retatrutide clinical trial

ClinicalTrials.gov is the federal registry of clinical studies, and it lists the retatrutide studies, including the phase 3 program. On September 23, 2026, a search for retatrutide as the intervention returned 33 records: 21 completed, 9 active but no longer recruiting, 2 recruiting, and 1 expanded access record marked available. [3] Most of the large phase 3 trials have finished enrolling, so openings are limited.

How to search:

  1. Go to ClinicalTrials.gov and enter "retatrutide" in the intervention or treatment field. The code name LY3437943 finds the same studies.
  2. Filter the recruitment status to "Recruiting" or "Not yet recruiting".
  3. Open each listing and read the eligibility criteria: age, BMI range, whether diabetes is required or excluded, and conditions that rule people out.
  4. Check the locations section for sites near you and use the listed contact for that site.
  5. Ask the study team what the trial involves before you agree to anything. Useful questions: how many visits, how long the trial lasts, whether there is a placebo group, and what happens when the study ends.

Two things to expect. Many trials randomize some participants to placebo, so enrolling does not guarantee you will receive the drug. And trial eligibility is strict by design. [3]

Is there early access to retatrutide?

Yes, in a narrow form. The manufacturer has registered a pre-approval expanded access program on ClinicalTrials.gov, marked available and last updated in August 2026. [4] It offers single-patient access for adults who meet all of these criteria: [4]

  • Age 18 or older.
  • BMI of 35 or higher despite adhering to and tolerating the highest available dose of approved weight management therapy.
  • Two or more serious or life-threatening obesity-related complications that are being treated.
  • Unable to join an ongoing retatrutide trial or a comparable investigational trial, because of eligibility rules or distance.
  • All standard options, including bariatric surgery, discussed through shared decision-making.

Requests are started by the treating physician on the patient's behalf, and the listing asks patients to go through their physician rather than contact the company directly. Availability depends on geography, supply, and individual assessment. [4]

This matches how FDA describes expanded access in general. Sometimes called compassionate use, it is a pathway for a patient with a serious or immediately life-threatening condition to receive an investigational product outside a trial when no comparable or satisfactory alternative exists and trial enrollment is not possible. [5] For most people seeking weight loss, the approved drugs count as a satisfactory alternative, which is why the program is limited to people who have already tried them.

Why online and compounded retatrutide is unlawful

Products sold as retatrutide online fall into two groups, and both are unlawful for human use.

"Research" products. FDA has warned companies that sold unapproved drugs containing retatrutide, labeled "for research purposes" or "not for human consumption," directly to consumers for human use with dosing instructions. The agency urges consumers not to buy these products, which are of unknown quality and may be harmful. [6] A 2026 case report described a man with type 1 diabetes hospitalized with vomiting, high ketones, and acute kidney injury after injecting an online product sold as retatrutide; a gut infection was also present, and the authors pointed to uncertain composition and dosing as part of the risk. [8]

"Compounded" products. No lawful compounded retatrutide exists. FDA has warned ingredient distributors for selling retatrutide to compounders and outsourcing facilities for repackaging it. [6] Any clinic or site offering it is offering an unapproved drug.

For athletes there is one more rule: retatrutide is prohibited at all times under section S0 of the WADA list, which covers substances without government approval for human use. [9]

What does retatrutide cost?

Retatrutide has no lawful price because it is not on the market; see retatrutide cost for approved GLP-1 prices as a reference point. If you enroll in a trial, ask the study team what the protocol provides and whether any costs fall to you; each ClinicalTrials.gov listing names a contact for every site. [3]

Lawful options while retatrutide is in trials

If you are weighing retatrutide for weight or blood sugar, approved drugs are available now through a prescriber, with FDA-reviewed labels and known safety data. Tirzepatide, a dual GIP and GLP-1 agonist, produced a mean weight change of minus 20.9% at 72 weeks on its top dose in its pivotal obesity trial, versus minus 3.1% on placebo. [10] Our tirzepatide vs retatrutide comparison shows how the two programs line up, with the caveat that no published trial has compared them directly.

Next steps:

For the trial results themselves, see retatrutide before and after, retatrutide side effects, and where the phase 3 program stands.

What's actually offered, and what that means for you

FDA has found online sellers and an ingredient distributor offering retatrutide anyway. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21]

What that means for you

  • Anyone who sells retatrutide outside a registered trial is taking a regulatory risk: FDA treats it as an unapproved new drug and has sent warning letters to sellers. [13]
  • No FDA oversight of the product: a product sold outside a trial is an unapproved drug, and FDA has not checked its safety, effectiveness, or quality. [13]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [22]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [23] [24]

If you're going ahead anyway

The only safe route to retatrutide is a registered clinical trial. No step below makes a product sold outside a trial lawful or safe. Each step is on the retatrutide page: what a research-use-only product means, and questions to ask.

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

How can I get retatrutide legally?

Only by enrolling in a registered clinical trial, or in narrow cases through the manufacturer's pre-approval expanded access program, which a treating physician must request. Retatrutide is not FDA approved, cannot be compounded, and the manufacturer states it is legally available only to trial participants. [2] [4] [6]

Is there early access to retatrutide?

There is a pre-approval expanded access program listed on ClinicalTrials.gov. It is for adults with a BMI of 35 or higher and at least two serious obesity-related complications whose obesity has not responded to the highest available dose of approved therapy and who cannot join a trial. Requests come from the treating physician, not the patient. [4]

Can a doctor prescribe retatrutide?

No. A prescription requires an approved drug or a lawful compounding basis, and retatrutide has neither. FDA says retatrutide cannot be used in compounding under federal law and has warned telehealth companies that marketed it. [6] [7]

Is it legal to buy retatrutide online?

Products sold online as retatrutide, including those labeled for research or not for human consumption, are unapproved drugs. FDA has warned sellers of these products and urges consumers not to buy them because their quality is unknown. [6]

Do clinical trial participants pay for retatrutide?

Ask the study team before you enroll. Each ClinicalTrials.gov listing names a contact for every site, and the team can explain what the protocol provides, what visits and tests involve, whether travel is reimbursed, and the chance of receiving placebo. [3]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]Manufacturer press release: topline results of the TRIUMPH-2 and TRIUMPH-3 phase 3 trials of retatrutide (July 23, 2026), not peer reviewed
  2. [2]Manufacturer press release: topline results of the TRIUMPH-1 phase 3 trial of retatrutide (May 21, 2026), not peer reviewed
  3. [3]ClinicalTrials.gov: registered studies with retatrutide as an intervention, accessed 2026-09-23
  4. [4]ClinicalTrials.gov NCT07629401: Pre-approval expanded access of retatrutide (LY3437943), status available, last updated August 2026
  5. [5]FDA: Expanded access (compassionate use)FDA
  6. [6]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including retatrutide and products falsely labeled for research (content current as of September 1, 2026)FDA
  7. [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA
  8. [8]Branine N. Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes and concurrent Shigella gastroenteritis. Cureus 2026PubMed 42669023, 2026
  9. [9]WADA Prohibited List, section S0 non-approved substancesWADA
  10. [10]Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022 (SURMOUNT-1)PubMed 35658024, 2022

More from the blog